Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

22P - Analyzing recurrence in colorectal cancer: Is a five years follow-up enough?

Date

27 Jun 2024

Session

Poster Display session

Presenters

Belén de Frutos González

Citation

Annals of Oncology (2024) 35 (suppl_1): S1-S74. 10.1016/annonc/annonc1477

Authors

B. de Frutos González1, F. Longo Munoz1, M. Viana Aragonés2, G. González Martín1, J.M.R. Sanz2, B.I. Morón1, I. Martínez Delfrade1, E. Corral de la Fuente1, J. Die-Trill1, J. Ocaña1, R. García Latorre1, E. Canales1, R. Ferreiro Monteagudo1

Author affiliations

  • 1 Hospital Universitario Ramon y Cajal, Madrid/ES
  • 2 Hospital Ramón y Cajal, Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 22P

Background

Colorectal cancer (CRC) is the third most diagnosed cancer in males and second in females all around the world. Surveillance programs are necessary to early detection recurrences, as 30% to 50% of patients treated for localized colorectal cancer will relapse. The aim of our study is to evaluate if prolonging the follow up more than five years is justified.

Methods

We retrospectively analyzed data from 573 patients diagnosed with localized CRC between 2009 and 2014. The follow up lasted until January 2024. We have analyzed the incidence of relapse and second tumors.

Results

Most of patients were men (55.92%), at a median age of 77. The stage IIA was the most frequent (41.64%) followed by IIIB (30.14%). The 52.79% of patients had a right side CCR. Chemotherapy was administrated to 261 patients (45.47%). Tumor recurrence was observed in 126 patients (21.95%). Liver relapse was the most frequent (27.27%) followed by pulmonary relapse (23.64%). Only 24 patients (4.18%) had local recurrence. Data show more relapses in patients with stage IIA (p 0.008) and IIIB (p 0.009). Recurrences after five years were observed in only 8 patients (6.35%) 2 being local, 2 hepatic and 4 pulmonary. Second tumors were diagnosed in 82 patients (11.89%). After five years of follow up we detected 10 patients with a second tumor and 2 with a relapse CCR and another tumor.

Conclusions

This study shows that tumor recurrences appear in 21.95% of patients, 6% of which after the 5 years follow up recommended in the guidelines, mostly on patients with stage IIA, suggesting the need to further study risk factors of this population and assess the need of further follow up.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.